Several additional cancer therapeutics have garnered interest in PAH, includinganastrazole and tamoxifen targeting estrogen signaling [89, 278];palbociclib-mediated cyclin-dependent kinase 4/9 (CDK4/9) inhibition [279]; andmodulation DNA damage/repair with the poly-ADP ribose polymerase inhibitorolaparib [182], highlighting the overlapping pathophenotypes between PAH andcancer as well as the hope that these drugs can be successfully translated to theclinical management of pulmonary vascular disease. The gene discussed is CDK4; the disease is pulmonary arterial hypertension.